Eli Lilly buys three biotechs for $4 billion, returning to vaccines

Eli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics, and Vaccine Company. The combined acquisitions total nearly $4 billion. This strategy marks Lilly's return to the infectious disease and vaccine market.

The deal for Curevo is valued at up to $1.5 billion. This acquisition includes a shingles vaccine candidate designed for improved tolerability.

LimmaTech Biologics adds vaccine programs targeting bacterial pathogens. Vaccine Company contributes a program for the Epstein-Barr virus.